New updates have been reported about Condor Software.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Condor Software has expanded its life sciences financial intelligence platform with an Advanced Analytics and Dynamic Scenario Suite designed to give R&D finance teams forward-looking, trial-level insight across the full financial lifecycle. The launch, which follows the company’s $24 million Series A round in March, positions Condor to move beyond automated accruals into integrated forecasting, scenario planning, and executive reporting.
The new suite allows R&D finance teams to build scenario-aware dashboards, simulate enrollment delays or site-activation changes without altering actuals, compare forecast versions, and share live views with executive stakeholders. Condor also previewed a forthcoming suite of clinical finance AI agents, described as embedded subject-matter experts that will detect patterns, flag risks, and automatically connect clinical operations data with financial rules.
According to VP of Product Nim Fox, the additions complete Condor’s coverage from financial close through strategic planning by creating a single, automatically updating source of truth as trial protocols, enrollment, and vendor terms evolve. The underlying platform is built on a clinical and financial ontology and knowledge graph developed with Big Four accounting firms, enabling explainable, unified data across trial design, enrollment metrics, site activity, vendor contracts, and financial policies.
Condor currently manages more than $19 billion in R&D spend for life sciences clients and aims to further embed itself in budgeting and portfolio decision-making as these analytics and AI capabilities roll out. For executives, the moves signal Condor’s strategy to deepen its role as a core system of intelligence between clinical operations and finance, potentially increasing switching costs for customers and enhancing the company’s growth prospects in a data- and compliance-intensive segment of the life sciences market.